Your browser is no longer supported. Please, upgrade your browser.
Settings
PSTV Plus Therapeutics, Inc. daily Stock Chart
PSTV [NASD]
Plus Therapeutics, Inc.
Index- P/E- EPS (ttm)-19.09 Insider Own- Shs Outstand3.81M Perf Week6.93%
Market Cap8.23M Forward P/E- EPS next Y-3.10 Insider Trans- Shs Float3.74M Perf Month-13.94%
Income-7.00M PEG- EPS next Q-0.66 Inst Own15.50% Short Float3.06% Perf Quarter-76.77%
Sales7.90M P/S1.04 EPS this Y78.90% Inst Trans- Short Ratio0.18 Perf Half Y-83.35%
Book/sh0.19 P/B11.37 EPS next Y- ROA-70.00% Target Price- Perf Year-86.29%
Cash/sh4.41 P/C0.49 EPS next 5Y- ROE- 52W Range1.78 - 24.45 Perf YTD-85.10%
Dividend- P/FCF- EPS past 5Y- ROI-65.50% 52W High-91.17% Beta1.58
Dividend %- Quick Ratio1.50 Sales past 5Y-11.40% Gross Margin93.30% 52W Low21.35% ATR0.25
Employees37 Current Ratio1.50 Sales Q/Q860.00% Oper. Margin-67.00% RSI (14)47.05 Volatility13.48% 12.18%
OptionableNo Debt/Eq55.50 EPS Q/Q99.80% Profit Margin- Rel Volume0.13 Prev Close2.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume632.48K Price2.16
Recom- SMA20-0.46% SMA50-11.00% SMA200-76.95% Volume80,572 Change0.93%
Dec-09-19 07:00AM  Plus Therapeutics to Present at Biotech Showcase 2020 GlobeNewswire +7.42%
Nov-25-19 07:00AM  Plus Therapeutics to Present at the LD Micro Main Event (XII) GlobeNewswire
Nov-14-19 04:05PM  Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results GlobeNewswire
Nov-04-19 07:00AM  Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 GlobeNewswire
Oct-15-19 09:20AM  Plus Therapeutics Receives $4.6MM Reimbursement Payment GlobeNewswire +12.24%
Sep-26-19 04:10PM  Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering GlobeNewswire
Sep-23-19 12:15PM  Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering GlobeNewswire -49.50%
06:10AM  Plus Therapeutics to Receive $4.6MM Reimbursement Payment GlobeNewswire
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.